Antiproliferative effects and DNA hypomethylation by 5-aza-2'-deoxycytidine in human neuroblastoma cell lines
- PMID: 7507741
- DOI: 10.1097/00001813-199312000-00004
Antiproliferative effects and DNA hypomethylation by 5-aza-2'-deoxycytidine in human neuroblastoma cell lines
Abstract
5-Aza-2'-deoxycytidine (5-AZA-CdR) is an inhibitor of DNA methylation, and its antileukemic activity has been shown in preclinical and clinical studies. This paper describes the ability of 5-AZA-CdR to inhibit DNA methylation, DNA synthesis and cell growth in several human neuroblastoma cell lines. The stability of cell growth inhibition was ascertained, as well as the ability of the metabolite thymidine to enhance the antiproliferative effect of 5-AZA-CdR. The activity of phosphorylating enzyme deoxycytidine kinase (dCK) was correlated to different levels of sensitivity in several cell lines. The results obtained indicate that 5-AZA-CdR may be an agent for the chemotherapy of neuroblastoma.
Similar articles
-
Effect of cytidine analogs on cell growth and differentiation on a human neuroblastoma line.Cell Biophys. 1989 Aug-Oct;15(1-2):67-77. doi: 10.1007/BF02991580. Cell Biophys. 1989. PMID: 2476228
-
5-Aza-2'-deoxycytidine as inducer of differentiation and growth inhibition in mouse neuroblastoma cells.Cell Differ Dev. 1989 Jun;27(1):47-55. doi: 10.1016/0922-3371(89)90043-9. Cell Differ Dev. 1989. PMID: 2475229
-
Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.Leukemia. 1997 Feb;11(2):175-80. doi: 10.1038/sj.leu.2400550. Leukemia. 1997. PMID: 9009076 Review.
-
Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine.Leuk Res. 1990;14(9):751-4. doi: 10.1016/0145-2126(90)90067-j. Leuk Res. 1990. PMID: 1700230
-
Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.Leukemia. 1997 Mar;11 Suppl 1:S1-6. Leukemia. 1997. PMID: 9130684 Review.
Cited by
-
ALKBH1 rs2267755 C>T polymorphism decreases neuroblastoma risk in Chinese children.J Cancer. 2024 Jan 1;15(2):526-532. doi: 10.7150/jca.89271. eCollection 2024. J Cancer. 2024. PMID: 38169562 Free PMC article.
-
Neuroblastoma and the epigenome.Cancer Metastasis Rev. 2021 Mar;40(1):173-189. doi: 10.1007/s10555-020-09946-y. Epub 2021 Jan 6. Cancer Metastasis Rev. 2021. PMID: 33404859 Free PMC article. Review.
-
Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma.Cancer Med. 2024 Nov;13(21):e70082. doi: 10.1002/cam4.70082. Cancer Med. 2024. PMID: 39501501 Free PMC article.
-
Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research.Mol Neurobiol. 2025 May;62(5):6423-6466. doi: 10.1007/s12035-024-04680-w. Epub 2025 Jan 13. Mol Neurobiol. 2025. PMID: 39804528 Review.
-
Epigenetic Dysregulation in MYCN-Amplified Neuroblastoma.Int J Mol Sci. 2023 Dec 3;24(23):17085. doi: 10.3390/ijms242317085. Int J Mol Sci. 2023. PMID: 38069407 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical